November 28, 2018

New Drug Approved to Treat Some Patients with Acute Myeloid Leukemia

Response rates as good as or better than other therapies

leukemia_650x450

FDA-approved treatment options are few and far between for patients with acute myeloid leukemia (AML), a disease characterized by genomic abnormalities.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Recently, however, researchers conducted a study that led to agency approval to treat a subset of AML patients — those with the genetic mutation IDH1 — with the drug ivosidenib.

“There are a paucity of treatment options that are FDA-approved for patients with AML,” says Mikkael Sekeres, MD, MS, Director of the Leukemia Program at Cleveland Clinic Cancer Center. “So this is welcome news for patients who have the IDH1 mutation.”

Median remission: nine months

Dr. Sekeres was one of a number of physician researchers involved in the clinical trial, which included a cohort of patients with AML. About 5 to 10 percent of patients with AML have the IDH1 mutation.

The investigators enrolled 258 patients in the trial; 179 had relapsed or refractory AML. The median age was 68 years, and 137 patients were male. The patients received 500 mg of ivosidenib daily with at least six months of follow-up.

Advertisement

Almost 75 percent of the patient population had received intensive standard chemotherapy in the past. About 33 percent had received another investigational therapy in the past.

“We saw complete remission with or without full hematologic recovery in 30 percent of the patients,” says Dr. Sekeres. “More importantly, the median duration of remission was almost nine months.”

Combining ivosidenib with chemotherapy

Dr. Sekeres says the drug caused about 10 percent of patients to have differentiation syndrome, a constellation of side effects including fever, fluid retention, weight gain and respiratory compromises along with a rise in white blood cell count. Differentiation syndrome can be managed with steroids and diuretics, he says.

“Overall, the drug caused elimination of minimal residual disease in a small percentage of patients, and I think, more importantly, it led to response rates and response durations that are as good as or better than other therapies we have available,” says Dr. Sekeres.

Advertisement

The next step will be to assess how well ivosidenib works in combination with standard chemotherapy, particularly in newly diagnosed AML patients with the IDH1 mutation.

“We do testing for genetic mutations in all patients who are diagnosed with leukemia or related cancers and, therefore, can identify approaches that are specific to an individual patient,” he says.

Related Articles

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024
Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

23-CNR-4221120 ASH 2023 Graphics-CQD
December 4, 2023
Ten ASH Presentations You Don’t Want to Miss

Cleveland Clinic oncologists’ selected abstracts

23-CNR-3741790-CQD-Hero-650×450 cell mobilization
April 24, 2023
Plerixafor is Effective for Hematopoietic Progenitor Cell Mobilization in Patients with AL Amyloidosis

On-demand stem cell mobilizer is an effective salvage strategy

CAR T-cell therapy
April 5, 2023
Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

CAR T-cell therapy for multiple myeloma
March 13, 2023
Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities

Research indicates strong rationale for expanding trial eligibility criteria

22-CNR-3245747-CQD-Hero-650×450 aplastic anemia
September 13, 2022
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Retrospective study yields clues to understanding risk of secondary myeloid neoplasms

Ad